231 related articles for article (PubMed ID: 11456381)
21. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial.
Serafini AN; Houston SJ; Resche I; Quick DP; Grund FM; Ell PJ; Bertrand A; Ahmann FR; Orihuela E; Reid RH; Lerski RA; Collier BD; McKillop JH; Purnell GL; Pecking AP; Thomas FD; Harrison KA
J Clin Oncol; 1998 Apr; 16(4):1574-81. PubMed ID: 9552068
[TBL] [Abstract][Full Text] [Related]
22. Use of samarium Sm 153 lexidronam for the treatment of dogs with primary tumors of the skull: 20 cases (1986-2006).
Vancil JM; Henry CJ; Milner RJ; McCoig AM; Lattimer JC; Villamil JA; McCaw DL; Bryan JN
J Am Vet Med Assoc; 2012 Jun; 240(11):1310-5. PubMed ID: 22607597
[TBL] [Abstract][Full Text] [Related]
23. Samarium-153-EDTMP in bone metastases.
Ahonen A; Joensuu H; Hiltunen J; Hannelin M; Heikkilä J; Jakobsson M; Jurvelin J; Kairemo K; Kumpulainen E; Kulmala J
J Nucl Biol Med (1991); 1994 Dec; 38(4 Suppl 1):123-7. PubMed ID: 7543288
[TBL] [Abstract][Full Text] [Related]
24. [Cost-effectiveness of samarium-153-EDTMP for the treatment of pain due to multiple bone metastases in hormone-refractory prostate cancer versus conventional pain therapy, in Portugal].
Macedo A; Araújo A; Melo FC; Nunes G; Cantinho G; Amorin I
Acta Med Port; 2006; 19(5):421-6. PubMed ID: 17376329
[TBL] [Abstract][Full Text] [Related]
25. Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer.
Singh A; Holmes RA; Farhangi M; Volkert WA; Williams A; Stringham LM; Ketring AR
J Nucl Med; 1989 Nov; 30(11):1814-8. PubMed ID: 2478681
[TBL] [Abstract][Full Text] [Related]
26. Formulation, preclinical evaluation, and preliminary clinical investigation of an in-house freeze-dried EDTMP kit suitable for the preparation of 177Lu-EDTMP.
Das T; Sarma HD; Shinto A; Kamaleshwaran KK; Banerjee S
Cancer Biother Radiopharm; 2014 Dec; 29(10):412-21. PubMed ID: 25409337
[TBL] [Abstract][Full Text] [Related]
27. Samarium 153Sm lexidronam.
Lamb HM; Faulds D
Drugs Aging; 1997 Nov; 11(5):413-8; discussion 419. PubMed ID: 9359026
[TBL] [Abstract][Full Text] [Related]
28. Samarium-153 ethylenediamine tetramethylene phosphonate therapy for bone pain palliation in skeletal metastases.
Tripathi M; Singhal T; Chandrasekhar N; Kumar P; Bal C; Jhulka PK; Bandopadhyaya G; Malhotra A
Indian J Cancer; 2006; 43(2):86-92. PubMed ID: 16790946
[TBL] [Abstract][Full Text] [Related]
29. Targeted radionuclide therapy for bone metastases.
Lewington VJ
Eur J Nucl Med; 1993 Jan; 20(1):66-74. PubMed ID: 7678397
[TBL] [Abstract][Full Text] [Related]
30. [Analgesic response and secondary effects in patients with osteoblastic metastasis, treated with Samarium 153 ethylenediaminotetramethylenephosphate].
Lovera C; Massardo T; Galleguillos MC; González P; Comparini B; Yáñez M; Fodor M; Gil MC; Araya G; Tomicic M
Rev Med Chil; 1998 Aug; 126(8):963-71. PubMed ID: 9830748
[TBL] [Abstract][Full Text] [Related]
31. [Treatment of painful bony metastases with Samarium 153-EDTMP in prostate carcinoma].
Mhiri A; Hassad R; Sellem A; Bahri H; Diakite R; Slim I; Mahersi M; Hammami H; Ben Adallah M; Ben Slimene MF
Tunis Med; 2007 Jul; 85(7):580-5. PubMed ID: 18064991
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain.
Sartor O; Reid RH; Bushnell DL; Quick DP; Ell PJ
Cancer; 2007 Feb; 109(3):637-43. PubMed ID: 17167764
[TBL] [Abstract][Full Text] [Related]
33. Samarium Sm 153 lexidronam for the palliative treatment of dogs with primary bone tumors: 35 cases (1999-2005).
Barnard SM; Zuber RM; Moore AS
J Am Vet Med Assoc; 2007 Jun; 230(12):1877-81. PubMed ID: 17571994
[TBL] [Abstract][Full Text] [Related]
34. Quantifying the radiation dosage to individual skeletal lesions treated with samarium-153-EDTMP.
van Rensburg AJ; Alberts AS; Louw WK
J Nucl Med; 1998 Dec; 39(12):2110-5. PubMed ID: 9867152
[TBL] [Abstract][Full Text] [Related]
35. 177Lu-EDTMP: a viable bone pain palliative in skeletal metastasis.
Chakraborty S; Das T; Banerjee S; Balogh L; Chaudhari PR; Sarma HD; Polyák A; Máthé D; Venkatesh M; Janoki G; Pillai MR
Cancer Biother Radiopharm; 2008 Apr; 23(2):202-13. PubMed ID: 18454689
[TBL] [Abstract][Full Text] [Related]
36. A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases.
Turner JH; Claringbold PG; Hetherington EL; Sorby P; Martindale AA
J Clin Oncol; 1989 Dec; 7(12):1926-31. PubMed ID: 2585026
[TBL] [Abstract][Full Text] [Related]
37.
Alavi M; Khajeh-Rahimi F; Yousefnia H; Mohammadianpanah M; Zolghadri S; Bahrami-Samani A; Ghannadi-Maragheh M
Cancer Biother Radiopharm; 2019 Jun; 34(5):280-287. PubMed ID: 30977670
[No Abstract] [Full Text] [Related]
38. Prospective 153Sm-EDTMP therapy dosimetry by whole-body scintigraphy.
Cameron PJ; Klemp PF; Martindale AA; Turner JH
Nucl Med Commun; 1999 Jul; 20(7):609-15. PubMed ID: 10423762
[TBL] [Abstract][Full Text] [Related]
39. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases.
Bayouth JE; Macey DJ; Kasi LP; Fossella FV
J Nucl Med; 1994 Jan; 35(1):63-9. PubMed ID: 7505819
[TBL] [Abstract][Full Text] [Related]
40. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer.
Farhanghi M; Holmes RA; Volkert WA; Logan KW; Singh A
J Nucl Med; 1992 Aug; 33(8):1451-8. PubMed ID: 1378887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
